Extrait

•To demonstrate the non-inferiority of GSK Biologicals’ DTPw-HBV-IPV(3 doses)/Hib vaccine compared to Poliorix co-administered with Zilbrix/Hib, -(full dose): in terms of seroprotection rates to the 3 poliovirus types and to demonstrate that the formulation induces at least a 2-fold increase in the geometric mean (GM) of the individual ratios (post- over pre-booster titres) for anti-poliovirus antibodies (Abs), 1 month after booster vaccination -(1/2 dose): in terms of seroprotection rates to the 3 poliovirus types and to demonstrate that the formulation induces at least a 2-fold increase in the GM of the individual ratios (post- over pre-booster titres) for anti-poliovirus abs, 1 month after booster vaccination -(1/3 dose): in terms of seroprotection rates to the 3 poliovirus types and to demonstrate that the formulation induces at least a 2-fold increase in the GM of the individual ratios (post- over pre-booster titres) for anti-poliovirus Abs, 1month after booster vaccination.

Critère d'inclusion

• Booster immunisation against poliomyelitis disease